Ortmann R, Bischoff S, Radeke E, Buech O, Delini-Stula A
Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(4):265-70. doi: 10.1007/BF00498511.
The antiserotonin properties of a series of neuroleptics, 5-HT-receptor blockers and some adrenoceptor antagonists were investigated in several in vivo test systems (L-5-HTP syndrome and 5-HT-paw edema in the rat) and in an in vitro test (isolated rat uterus preparation). The results were compared to the results obtained with these drugs in an in vivo 3H-spiperone binding assay in the rat. The computations of the relative ED50 (or IC50) values obtained in different test procedures showed that the ability of drugs to bind to 5-HT receptors labelled by 3H-spiperone in the rat frontal cortex correlates fairly well with their potencies to inhibit the L-5-HTP syndrome or 5-HT-induced rat pawedema (Spearman rank correlation coefficient, r = 0.80 and 0.79 respectively, n = 22). In an in vitro test (rat uterus) the estimated 5-HT-receptor blocking potency of the tested drugs did not, however, correlate with any of the in vivo measures used for this purpose. The results suggest, therefore, that for the determination of central antiserotonin effects of drugs in the rat, functional in vivo tests (L-5-HTP syndrome or 5-HT-induced rat paw-edema) could yield about the same information as the specific, in vivo 3H-spiperone binding assay. The 5-HT-receptor type mediating the behavioral responses to L-5-HTP is tentatively defined as a 5-HT2 receptor.
在多种体内试验系统(大鼠的L-5-羟色胺酸综合征和5-羟色胺致爪水肿)以及一种体外试验(离体大鼠子宫制备)中,研究了一系列抗精神病药物、5-羟色胺受体阻滞剂和一些肾上腺素能受体拮抗剂的抗5-羟色胺特性。将这些结果与在大鼠体内3H-螺哌隆结合试验中使用这些药物所获得的结果进行了比较。对在不同试验程序中获得的相对半数有效剂量(ED50)或半数抑制浓度(IC50)值的计算表明,药物与大鼠额叶皮质中由3H-螺哌隆标记的5-羟色胺受体结合的能力,与它们抑制L-5-羟色胺酸综合征或5-羟色胺诱导的大鼠爪水肿的效力相当吻合(斯皮尔曼等级相关系数,r分别为0.80和0.79,n = 22)。然而,在体外试验(大鼠子宫)中,受试药物的估计5-羟色胺受体阻断效力与为此目的所采用的任何体内测量值均无相关性。因此,结果表明,对于测定大鼠体内药物的中枢抗5-羟色胺作用,功能性体内试验(L-5-羟色胺酸综合征或5-羟色胺诱导的大鼠爪水肿)所产生的信息与特异性的体内3H-螺哌隆结合试验大致相同。介导对L-5-羟色胺酸行为反应的5-羟色胺受体类型暂定为5-HT2受体。